Roche backs away from Chugai but embraces InterMune, Merck rumored on track to score first PD-1 approval, a new Ebola strain may have surfaced and JNJ scoops up experimental anti-TNF.
Phase-II data show reduced hepatitis-C RNA levels among HIV-positive patients, the drugmaker shared at a medical meeting. Boehringer also released co-infection data.
The GlaxoSmithKline-Pfizer-Shionogi joint venture scored an FDA approval in August.
The Kaiser Family Foundation's just-launched website, funded by Gilead, addresses healthcare reform from a distinct perspective.
Adding Epzicom to Tivicay in a once-daily cocktail could further boost GSK's HIV franchise, and possibly chip away at Atripla's dominance.
Gilead's Striblid faces hurdle in Germany, Boehringer and Roche team up for companion diagnostic effort and Wisconsin hospital system says no to samples
CDC finds that non-Medicare adults make up the majority of preventable heart attack and stroke cases; a Facebook study shows groups can influence HIV screening; and a Shire ADHD drug gets a "no" from Germany
The GSK-Pfizer-Shionogi daily HIV medication gets the regulatory all-clear. The approval could put BMS/Gilead's best-selling daily med Atripla on the defensive.
A two-year study shows Gilead's Quad pill outpaces an older combination drug over two years, and GSK is seeking to expand its oncology presence.
Messaging around HIV testing now mixes individual concerns with community protection. Recent efforts, like those of the CDC and Greater than AIDS, try to make getting tested an empowering act.
Pharma pared back its ad spend in 2012, a baby born HIV-positive is virus-free two-and-a-half years later, and Boston Children's Hospital is making its own apps.